Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 39th Annual Meeting of the Infectious Diseases Society of America
HIV/AIDS: Antiretroviral Therapy (Poster Session 87)

Coverage provided by Douglas T. Dieterich, M.D.

October 27, 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • Clinical Experience of Amprenavir (APV) Following Nelfinavir (NFV) Use (Poster 694)
    Authored by Stephen L. Becker, Pacific Horizon Medical Group, San Francisco, CA; Douglas T. Dieterich, Liberty Medical Group, New York, NY; Gregory P. Fusco, GlaxoSmithKline, Research Triangle Park, NC


This is a study from the CHORUS database with which I was involved. It looked at patients in the database who were switched from nelfinavir (NLF) to amprenavir or amprenavir/ritonavir (APV/RTV) regimens. The real-life question that this study answers is, "is there cross-resistance between nelfinavir and amprenavir?"

The answer gleaned from this data is that there is apparently no cross-resistance between nelfinavir and amprenavir. This clinical data supports the genotypic and phenotypic data that amprenavir salvage should work in nelfinavir-experienced patients. Only 17% of patients taking amprenavir for a median of 385 days discontinued due to side effects. This suggests that amprenavir is well tolerated. Other randomized trials addressing this question are in progress, however this is good news, suggesting that there is a good option after nelfinavir failure.


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
More Research on Switching HIV Treatments



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement